Marinus Pharmaceuticals Inc (MRNS)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Marinus Pharmaceuticals Inc chart...

About the Company

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides

Exchange

NASDAQ

Website

marinuspharma.com

$30M

Total Revenue

142

Employees

$483M

Market Capitalization

-3.36

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MRNS News

Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights

2d ago, source:

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

1d ago, source:

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to ...

Buy Rating Affirmed for Marinus Pharmaceuticals with Promising Outlook for Ganaxolone in RSE Treatment

2d ago, source:

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Marinus (MRNS – Research Report), with a price ...

Marinus Pharmaceuticals files patent for injectable ganaxolone formulation for treating seizure disorders

16d ago, source: Pharmaceutical Technology

Discover Marinus Pharmaceuticals' patent for an injectable ganaxolone formulation to treat seizures, strokes, and brain injuries. Learn about the key components and ratios for enhanced treatment.

Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?

8d ago, source: Zacks.com on MSN

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

BTIG upgrades Nuvation to buy, cites AnHeart acquisition

on MSN ago, source:

BTIG has upgraded Nuvation Bio (NUVB) to buy, citing the company’s plans to acquire AnHeart Therapeutics. Read more here.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript

3d ago, source: Insider Monkey

DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among ... She has served as the Chief Medical Officer for Epygenix Therapeutics, Marinus Pharmaceuticals Pharmaceuticals, Cubist ...

SNDL leads cannabis decliners after Q4 results

on MSN ago, source:

Cannabis company SNDL (CNSL) falls even as its Q4 2023 results indciate a 3% YoY increase in revenue and a 45% YoY fall in net operating loss. Read more here.

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates

22d ago, source: 雅虎財經

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -15.63% and 7.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the ...

MRNS Jul 2024 16.000 call

12d ago, source: Yahoo Finance

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript March 5, 2024 Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.74 EPS, expectations were ...

Amring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic Acquisition

15d ago, source: MyChesCo on MSN

BERWYN, PA — Amring Pharmaceuticals Inc. has announced a corporate name change to Nordic Pharma, Inc., marking a new chapter ...

Ocugen, Inc. Welcomes Dr. Huma Qamar as New Chief Medical Officer to Spearhead Clinical Developments

4d ago, source: MyChesCo on MSN

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...